2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2091

Mucosal-Associated Invariant T (MAIT) Cells As a Potential Therapeutic Target for Systemic Lupus Erythematosus
Abstract Number: 2784

Multi Modal Imaging Algorithm to Improve the Accuracy for the Diagnosis of Giant Cell Arteritis
Abstract Number: 609

Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice
Abstract Number: 921

Multi-Omics Analysis Identifies a Gene Signature Associated with the Clinical Response to Anti-TNF Therapy in Rheumatoid Arthritis
Abstract Number: 1102

Multi-Organ RNA-Sequencing of Patients with Systemic Sclerosis (SSc) Finds That Intrinsic Subsets Are Conserved across Organ Systems
Abstract Number: 2958

Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
Abstract Number: 2972

Multicentric Reticulohistiocytosis (1980-2017): A Rare Disease, Commonly Associated with Malignancy and Autoimmunity
Abstract Number: 2611

Multidrug Resistant AxSpA: No Advantage of Switching Class in Patients with Inadequate Response to Two Prior TNFi Agents
Abstract Number: 2320

Multimorbidity Is Associated with Hip Fractures in Both Women and Men and across Different Races
Abstract Number: 2033

Multiparameter Mass Cytometry By Time-of-Flight Spectrometry (CyTOF) Phenotyping in Pediatric Localized Scleroderma
Abstract Number: 1935

Multiple Dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP5094, an Anti-Alpha9 Integrin Monoclonal Antibody, in Patients with Rheumatoid Arthritis on Methotrexate
Abstract Number: 2832

Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
Abstract Number: 2917

Multiplex Serum Biomarker Analysis before and during Therapy with Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 1737

Multiplexed Autoantibody Profiles in a Systemic Sclerosis Clinical Trial Comparing Autologous Hematopoietic Stem Cell Transplantation and Cyclophosphamide
Abstract Number: 2006

Murine Ear Wound Cartilage Superhealer Trait Is Associated with Gut Microbiota Changes and Is Transferable to Non-Healer Mice By Gut Microbiome Transplant

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].